CRISPR Therapeutics AG
Technology · EUR · F
Price
€42.485
Cap
€11.77M
Earnings
—
30d Trend
-10.4%
65% annualised over 90 days
BRAIN47 SIGNAL
Raw weighted: 48×Macro 0.99 (−1%)=48
RISK
QUALITY
MOMENTUM
TECHNICAL
FUNDAMENTALS
Macro: neutral (×0.99) - Fear/Greed: 65 (Greed) - Data: 100%
BRAIN47 HORIZON ANALYSIS
Limited short-term thesis
BRAIN47'S ASSESSMENT
I rate CRISPR Therapeutics AG at 48/100 — a MODERATE reading on the Brain47 Signal. The strongest factor is momentum at 68/100. I classify this as a growth position with the strongest thesis on a short-term horizon.
PAST PERFORMANCE
1 MONTH
+2.8%
3 MONTHS
-11.0%
12 MONTHS
+43.8%
Trailing returns — past performance, not a projection.
DETAILED ANALYSIS
Limited short-term thesis. Momentum (68) and Technical (54) are the primary strengths. I note that fundamentals is the weakest area at 15/100 — this warrants monitoring. Historical volatility is elevated at 65%. I classify this as a growth position — strong momentum combined with growth potential points to capital appreciation.
Want full analysis on every stock?
Brain47 provides AI-powered research across 72,000+ instruments. Stocks, ETFs, REITs and more.
Join Brain47 — FreeGenerated by Brain47 AI. Educational research only. Not financial advice. Brain47 is not authorised by the FCA to provide investment advice.